Here’s what you should note:
1. Patient susceptibility to diseases as well as microbial agent’s nature and virulence are spurring market expansion.
2. Growing HAI prevalence, in tandem with a lack of awareness and insufficient training and infection control practices, is also fueling growth.
3. Additional factors leading to growth include:
• Inadequate healthcare infrastructure
• Low healthcare expenditures
• More chronic diseases with extended hospital stays
4. Microbial resistance growth and people using off-label antiseptics and drugs are driving market expansion.
5. In 2016, the market totaled $23.7 billion.
6. The report expects the market to increase at a 7.3 percent compound annual growth rate through 2022, hitting $36.16 billion.
More articles on quality and infection control:
Opioid abuse drops when providers check patients’ past prescriptions: 4 things to know
Nearly 22k US malaria-related hospitalizations reported in 14 years: 7 takeaways
AAFP submits physician-focused alternative payment model: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
